Efficacy and Safety of Dupilumab vs Narrowband UVB for the Treatment of Chronic Hand Dermatitis: A Retrospective Study.
作者信息
Branyiczky Miranda K, Sakka Noor, Bawazir Mohammed, Cy Ajith, Abu-Hilal Mohannad
机构信息
Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
University of Jordan School of Medicine, Amman, Jordan.
出版信息
Acta Derm Venereol. 2025 May 26;105:adv42198. doi: 10.2340/actadv.v105.42198.
Abstract
摘要
相似文献
1
Efficacy and Safety of Dupilumab vs Narrowband UVB for the Treatment of Chronic Hand Dermatitis: A Retrospective Study.度普利尤单抗与窄谱中波紫外线治疗慢性手部皮炎的疗效和安全性：一项回顾性研究
Acta Derm Venereol. 2025 May 26;105:adv42198. doi: 10.2340/actadv.v105.42198.
2
Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema.局部窄谱中波紫外线光疗与局部补骨脂素加长波紫外线照射治疗慢性手部湿疹的对比研究
Photodermatol Photoimmunol Photomed. 2007 Feb;23(1):10-4. doi: 10.1111/j.1600-0781.2007.00258.x.
3
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
4
Efficacy and safety of dupilumab in chronic hand eczema: a systematic review.度普利尤单抗治疗慢性手部湿疹的疗效与安全性：一项系统评价
Arch Dermatol Res. 2025 Feb 20;317(1):441. doi: 10.1007/s00403-025-03947-z.
5
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).度普利尤单抗治疗青少年中重度特应性皮炎的长期疗效和安全性：III 期开放标签扩展试验（LIBERTY AD PED-OLE）的第 52 周结果。
Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14.
6
A Short Cycle of Narrow-Band UVB Phototherapy in the Early Phase of Dupilumab Therapy Can Provide a Quicker Improvement of Severe Atopic Dermatitis.在度普利尤单抗治疗的早期进行短周期窄谱 UVB 光疗可以更快地改善重度特应性皮炎。
Dermatology. 2021;237(3):407-415. doi: 10.1159/000512456. Epub 2021 Jan 5.
7
Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up).乌帕替尼与度普利尤单抗治疗中重度特应性皮炎成人及青少年的疗效与安全性：一项开放标签、随机、疗效评估者设盲的头对头IIIb/IV期研究（升级研究）第16周结果
Br J Dermatol. 2024 Dec 23;192(1):36-45. doi: 10.1093/bjd/ljae404.
8
Systematic review and estimated cost-efficacy of biologics compared with narrowband ultraviolet B light for the treatment of moderate to severe psoriasis and atopic dermatitis.系统评价和生物制剂与窄谱中波紫外线治疗中重度银屑病和特应性皮炎的成本效益估计。
Int J Dermatol. 2023 Aug;62(8):986-999. doi: 10.1111/ijd.16677. Epub 2023 Apr 17.
9
Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides.窄谱 UVB 与 PUVA 治疗早期蕈样肉芽肿病的疗效比较。
J Eur Acad Dermatol Venereol. 2010 Jun;24(6):716-21. doi: 10.1111/j.1468-3083.2009.03500.x. Epub 2009 Nov 19.
10
Retrospective study of the efficacy of narrowband UVB and acitretin.窄谱中波紫外线与阿维A疗效的回顾性研究
J Dermatolog Treat. 2003;14 Suppl 2:17-20. doi: 10.1080/jdt.14.s2.17.20.
本文引用的文献
1
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study.度普利尤单抗治疗手部湿疹的疗效与安全性：一项回顾性研究。
J Clin Med. 2024 Mar 24;13(7):1876. doi: 10.3390/jcm13071876.
2
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.度普利尤单抗治疗可改善特应性手足性皮炎患者的体征、症状、生活质量和工作生产力：一项 3 期、随机、双盲、安慰剂对照试验的结果。
J Am Acad Dermatol. 2024 Jun;90(6):1190-1199. doi: 10.1016/j.jaad.2023.12.066. Epub 2024 Feb 1.
3
A Review of Existing and New Treatments for the Management of Hand Eczema.手部湿疹治疗的现有和新疗法综述。
J Cutan Med Surg. 2023 Sep-Oct;27(5):493-503. doi: 10.1177/12034754231188325. Epub 2023 Jul 27.
4
Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.度普利尤单抗治疗阿利维 A 酸应答不足或不耐受的重度慢性手部湿疹患者的疗效和安全性：一项随机、双盲、安慰剂对照的 IIb 期概念验证研究。
Br J Dermatol. 2023 Sep 15;189(4):400-409. doi: 10.1093/bjd/ljad156.
5
Treatment of chronic hand eczema with dupilumab-A retrospective follow-up study.度普利尤单抗治疗慢性手部湿疹——一项回顾性随访研究
J Eur Acad Dermatol Venereol. 2023 Apr;37(4):e557-e559. doi: 10.1111/jdv.18805. Epub 2022 Dec 14.
6
Guidelines for diagnosis, prevention, and treatment of hand eczema.手部湿疹的诊断、预防及治疗指南。
Contact Dermatitis. 2022 May;86(5):357-378. doi: 10.1111/cod.14035. Epub 2022 Mar 3.
7
Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab.三例非特应性角化过度型手部湿疹患者接受度普利尤单抗治疗。
Contact Dermatitis. 2021 Feb;84(2):124-127. doi: 10.1111/cod.13693. Epub 2020 Oct 1.
8
Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab.使用度普利尤单抗成功治疗重度难治性急性复发性水疱性慢性手部湿疹。
Contact Dermatitis. 2020 Jul;83(1):37-38. doi: 10.1111/cod.13501. Epub 2020 Mar 19.
9
Interventions for hand eczema.手部湿疹的干预措施。
Cochrane Database Syst Rev. 2019 Apr 26;4(4):CD004055. doi: 10.1002/14651858.CD004055.pub2.
10
A Retrospective Review of Dupilumab for Hand Dermatitis.度普利尤单抗治疗手部皮炎的回顾性研究
Dermatology. 2019;235(3):187-188. doi: 10.1159/000496481. Epub 2019 Feb 6.
Zotero 插件